Pracinostat: Completed Phase II enrollment

MEI completed enrollment of 108 patients with previously untreated intermediate-2 or high-risk MDS in a double-blind, placebo-controlled, U.S. Phase II trial evaluating 60 mg oral pracinostat 3 times a week for the first 3 weeks of a 4-week cycle plus subcutaneous or IV Vidaza azacitidine. Pracinostat is also in Phase II testing in combination with Vidaza for first-line treatment of acute myelogenous leukemia (AML) and in combination with Vidaza or Dacogen decitabine in patients with refractory MDS. ...